Key result
The overall 5-year survival rate for all patients with adrenocortical cancer is 30%, though patients with tumors <5 cm and no metastases have a median survival exceeding 10 years.
Why the study?
What are the current evidence-based diagnosis, treatment, and outcomes for patients with adrenocortical cancer?
Population
Patients with adrenocortical cancer (ACC)
Design
Review
Authors
Loading...
Stage-specific survival informs counseling in adrenocortical cancer; leaves open optimal adjuvant and systemic strategies.
Systematic Review (n=2,049)
What are the current evidence-based diagnosis, treatment, and outcomes for patients with adrenocortical cancer?
Adrenocortical cancer remains a disease with a poor overall prognosis (30% 5-year survival), though early-stage disease treated with surgery and advanced disease treated with mitotane-based combination chemotherapy show improved outcomes.
Radu Mihai (2015) conducted a systematic review in Adrenocortical cancer (n=2,049). Adrenocortical cancer treatments (surgery, mitotane, chemotherapy) was evaluated. The overall 5-year survival rate for all patients with adrenocortical cancer is 30%, though patients with tumors <5 cm and no metastases have a median survival exceeding 10 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: